Engineered immune cells take on recurrent head and neck cancer
NCT ID NCT06096038
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment called iC9-CAR.CSPG4 T cells for people with head and neck cancer that has come back after standard treatments. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to find a safe dose and to see if the treatment can control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iC9-CAR.CSPG4 T cells (a type of CAR T-cell therapy)
What this could lead to
If successful, this could lead to a new treatment option for patients with head and neck cancer that has returned after standard therapy.
What could go wrong
This is an early-phase trial with only 33 participants, so results may not apply to everyone. The treatment can cause serious side effects like cytokine release syndrome and nerve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••